Myasthenia Gravis Trial Set for CAR T CABA-201
The chimeric antigen receptor T-cell therapy (CAR T) from Cabaletta Bio has already been cleared for trials in systemic lupus erythematosus, myositis, and systemic sclerosis.
Source: ajmc.com
📰 Caba 201 News
Caba 201 News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Caba 201. Real-time updates on events, politics, business and more.
Cabaletta Bio Gets FDA's Nod For CABA-201 INDA For Generalized Myasthenia Gravis
Clinical-stage biotechnology company Cabaletta Bio, Inc. (CABA) Monday announced that FDA has allowed its Investigational New Drug or IND application for CABA-201 to proceed for a Phase 1/2 study in patients with generalized myasthenia gravis.
Source: rttnews.com